![](https://endpts.com/wp-content/uploads/2023/12/Amit-Etkin-Alto-Neuroscience-tile.jpg)
Amit Etkin, Alto Neuroscience CEO
Mid-stage CNS biotech Alto Neuroscience plots $89M IPO
Alto Neuroscience joined Fractyl Health in outlining its IPO price range on Monday morning as the two biotechs look to build on the momentum generated …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.